



<b>Legal Name</b>	University of California, Los Angeles
<b>Headquarters</b>	405 Hilgard Avenue Los Angeles
<b>Contact Email:</b>	<a href="mailto:ecorrin@mednet.ucla.edu">ecorrin@mednet.ucla.edu</a>
<b>Phone Number:</b>	+1 310-825-4321
<b>Website:</b>	<a href="https://ucla.edu">https://ucla.edu</a>
<b>LinkedIn:</b>	<a href="#">View on LinkedIn</a>
<b>Facebook:</b>	<a href="#">View on Facebook</a>
<b>Twitter:</b>	<a href="#">View on Twitter</a>
<b>Categories</b>	Education, Higher Education, Universities

## Overview

The University of California, Los Angeles (UCLA) is a public land-grant research university located in Los Angeles, California, USA. It was established in 1881 as a normal school. UCLA offers 337 undergraduate and graduate degree programs across numerous disciplines, enrolling approximately 31,600 undergraduate and 14,300 graduate and professional students annually. It received 174,914 undergraduate applications for Fall 2022, making it the most applied-to university in the United States. UCLA is organized into the College of Letters and Science and twelve professional schools, including the schools of Arts and Architecture, Medicine, Law, and Engineering among others. UCLA's athletic teams compete as the Bruins in the Big Ten Conference and have won 123 NCAA team championships and 270 Olympic medals.

## History

In March 1881, state senator Reginaldo Francisco del Valle succeeded in having the California State Legislature authorize a southern branch of the California State Normal School to train teachers. The Los Angeles branch opened on August 29, 1882. It became independent and was named Los Angeles State Normal School in 1887. It moved to its current location in Westwood in 1929 with the completion of four buildings, known today as Powell Library, Royce Hall, the Humanities Building, and the Chemistry Building. The institution became the Southern Branch of the University of California in 1919 and was renamed the University of California at Los Angeles (UCLA) in 1927. UCLA awarded its first bachelor's degrees in 1925 and its first doctorate in 1936. The institution grew significantly under Chancellor Franklin David Murphy from 1960, securing its position as a prominent university.

## Administration

The current Chancellor of UCLA is Gene D. Block, who has served this role since 2007.

## Research Centers

UCLA hosts numerous research centers including but not limited to: UCLA Broad Stem Cell Research Center, California NanoSystems Institute, Center for Embedded Network Sensing, Division of Social Sciences, Institute for Quantitative Biosciences, and the Enormous Toroidal Plasma Device. The Ronald Reagan UCLA Medical Center is a major hub for medical research and education. Other notable research centers include the Institute for Social Science Research and the Semel Institute for Neuroscience and Human Behavior.

### University Collaborators

Opportunities for collaboration or sales of 'DC power systems, switchgear, thermal management products, integrated rack systems, and monitoring and control systems for digital infrastructure' are significant at UCLA. Potential areas include: Engineering and Applied Science school, Data Center facilities within the campus, Medical Research laboratories particularly in the Ronald Reagan UCLA Medical Center, Broad Stem Cell Research Center and California NanoSystems Institute. Emphasis can be placed on data center infrastructure and advanced research labs which could benefit greatly from state-of-the-art digital infrastructure systems.

### Statistics

UCLA is often ranked within the top 20 universities globally. Based on available data, UCLA ranks among the top 15 to 20 universities worldwide.

### Leadership team



**Name:** Stuart Banner

**Position:** Norman Abrams Professor of Law

**Location:** N/A

**LinkedIn:** N/A

**About:** Stuart Banner teaches Property, the Supreme Court Clinic, and a variety of other courses. Professor Banner is a legal historian who has written about a wide range of topics in American and British legal history. His books include *The Baseball Trust: A History of Baseball's Antitrust Exemption* (Oxford University Press, 2013); *American Property: A History of How, Why, and What We Own* (Harvard University Press, 2011); *Who Owns the Sky? The Struggle to Control Airspace from the Wright Brothers On* (Harvard University Press, 2008); *Possessing the Pacific: Land, Settlers, and Indigenous People from Australia to Alaska* (Harvard University Press, 2007); *How the Indians Lost Their Land: Law and Power on the Frontier* (Harvard University Press, 2005); *The Death Penalty: An American History* (Harvard University Press, 2002); *Legal Systems in Conflict: Property and Sovereignty in Missouri, 1750-1860* (University of Oklahoma Press, 2000); and *Anglo-American Securities Regulation: Cultural and Political Roots, 1690-1860* (Cambridge University Press, 1998). He has received fellowships from the National Endowment for the Humanities, the John Simon Guggenheim Memorial Foundation, the Fulbright Scholar Program, and the Woodrow Wilson International Center for Scholars. Professor Banner graduated from Stanford Law School, where he was articles editor of the *Stanford Law Review*. He clerked for Judge Alex Kozinski of the U.S. Court of Appeals for the Ninth Circuit and Justice Sandra Day O'Connor of the U.S. Supreme Court. He practiced law at Davis Polk & Wardwell and at the Office of the Appellate Defender, both in New York. Before coming to UCLA, he taught at Washington University in St. Louis.



**Name:** Achuta Kadambi

**Position:** Assistant Professor

**Location:** N/A

**LinkedIn:** [View on LinkedIn](#)

## Organization Profile

---

**About:** Achuta Kadambi currently works as an Assistant Professor for the University of California. He previously worked at Akasha Imaging as a Co-Founder. Achuta Kadambi attended Massachusetts Institute of Technology.



**Name:** Michael Phelps

**Position:** Director

**Location:** N/A

**LinkedIn:** [View on LinkedIn](#)

**About:** Michael Phelps is an Executive Director at Early Manuscripts Electronic Library.



**Name:** Antoni Ribas

**Position:** Associate Professor

**Location:** N/A

**LinkedIn:** [View on LinkedIn](#)

**About:** Antoni Ribas joined UCLA as Associate Professor. Antoni Ribas, M.D., Ph.D. is Professor of Medicine, Professor of Surgery, and Professor of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA), Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC) and the Chair of the Melanoma Committee at SWOG. He is the Vice-President of the Society for Melanoma Research (SMR). He trained at the University of Barcelona and completed postdoctoral research and clinical fellowships at UCLA. He is a member of the American Society of Clinical Investigation (ASCI). Ribas is a physician-scientist who conducts laboratory and clinical research in malignant melanoma, focusing on gene-engineered adoptive cell transfer (ACT) therapies, anti-CTLA4 antibodies, anti-PD-1 antibodies, BRAF and MEK inhibitors and nanoparticle-siRNA. His NIH, State of California and private foundation-supported research laboratory develops models of disease to test new therapeutic options and studies mechanism of action of treatments in patients.



**Name:** Michelle Popowitz

**Position:** Assistant Vice Chancellor for Research

**Location:** N/A

**LinkedIn:** [View on LinkedIn](#)

**About:** Michelle Popowitz is an Assistant Vice Chancellor for Research of University of California, Los Angeles. She attended Loyola Law School, Los Angeles.

## Most Recent News Articles

**Title:** Meet Artemis The robot set to dribble past Messi and dominate the World Cup.

**Publication Date:** 20/11/2024

## Organization Profile

---

**Abstract:** When you think of elite footballers, names like Lionel Messi, Cristiano Ronaldo, and Kylian Mbappé come to mind. But the latest contender making waves isn't human at all. Meet ARTEMIS, a groundbreaking humanoid robot from UCLA, poised to shake up the world of football. ARTEMIS More Than Just a Machine ARTEMIS, which stands for Advanced Robotic Technology for Enhanced Mobility and Improved Stability, is designed to play football with ambitions so lofty that it aims to challenge human legends. Engineered by top researchers at the University of California, Los Angeles, ARTEMIS is equipped with cutting-edge technology that blurs the lines between biomechanics and robotics. In terms of speed, ARTEMIS has already set records. This humanoid is capable of walking at an impressive 2.1 metres per second, making it the fastest walking humanoid robot in the world. According to UCLA researchers, its swift pace could create chaos on the pitch, surpassing traditional robotic limitations

**URL:** <https://www.livemint.com/technology/meet-artemis-the-robot-set-to-dribble-past-lionel-messi-cristiano-ronaldo-and-dominate-the-fifa-world-cup-2026-watch-11732063263039.html>

**Title:** Turning Exercise into Medicine The Quest for an 'Exercise-in-a-Pill' Solution for Brain Health.

**Publication Date:** 19/11/2024

**Abstract:** Ah, exercise the pice de rsistance of human existence! It seems were constantly bombarded with Get up and move! messages, like an overenthusiastic gym coach whos had one too many energy drinks. But who can blame them? Regular exercise is touted as a magic potion for everything from a better mood to a less fuzzy brain. Now, a new study from the brainiacs at the University of Southern California and UCLA is taking this whole exercise is the key to everything notion and shaking it up like a cocktail on a Saturday night! Turns out, theyre exploring the possibility of bottling up the benefits of exercise into a drug. Genius! Who needs sweat and sore muscles when you can just pop a pill, right? For those of you whove balked at the idea of jumping around like a sugar-fueled toddler, fret not! Regular activity doesnt just help keep the muffin top at bay;

**URL:** <https://www.archyde.com/turning-exercise-into-medicine-the-quest-for-an-exercise-in-a-pill-solution-for-brain-health/>

**Title:** OpenSea users head to arbitration; Tokenized security examined.

**Publication Date:** 19/11/2024

**Abstract:** Two months after instituting legal action against non-fungible token (NFT) platform OpenSea for allegedly offering unregistered securities, aggrieved users are heading toward arbitration following the platforms tough stance. In a court document, OpenSea confirmed that it will remain firm on its decision to compel the users to explore arbitration before proceeding to court. The firm is basing its decision on its terms of use, which it says the plaintiffs had previously agreed to. A quick glance at the terms of use reveals that the dispute between the firm and users will be arbitrated in JAMS, a full-service alternative dispute resolution (ADR) provider in the United States. Federal court judge Cecilia Altonaga greenlighted OpenSea to file the motion compelling the users to seek arbitration before pursuing their claims in court. In September, Itai Bfronshtein and Anthony Shnayderman filed a calss-action lawsuit against Ozone Networks, the company behind OpenSea and its affiliated business. The plaintiffs

**URL:** <https://coingeek.com/opensea-users-head-to-arbitration-tokenized-security-examined/>

**Title:** As Trump threatens deportations, colleges tread carefully.

**Publication Date:** 18/11/2024

**Abstract:** The president of Wesleyan University wasted no time addressing his students concerns about the election results after Donald Trumps victory on Nov. 5. Michael Roth put out a statement the next day reflecting on the four years aheadand highlighting how the university might respond to the potential deportations of undocumented students. He was ready; like other longtime higher ed leaders, hed been there before. As we said after the election of 2016 Wesleyan will remain committed to principles of nondiscrimination, including equal protection under the law, regardless of national origin or citizenship, Roth wrote. The University will not voluntarily assist in any efforts by the federal government to deport our students, faculty or staff solely because of their citizenship status, he vowed. But as Roth subsequently told Inside Higher Ed, there are limits to the assurances Wesleyan can give. The university will of course comply with the law. If we get subpoenas, well

**URL:** <https://www.insidehighered.com/news/government/politics-elections/2024/11/18/trump-threatens-deportations-colleges-tread-carefully>

## Organization Profile

---

**Title:** The Isolation and Characterization of Perlucin in Pacific Abalone, *Haliotis discus hannai* A Shell Morphogenic Protein with Potential Responses to Thermal Stress and Starvation.

**Publication Date:** 18/11/2024

**Abstract:** ) make up 9599% while organic matter constitutes 0.15% [ 1 ]. In nature, a myriad of living organisms synthesize biominerals for mineral ion storage, tissues, soft-body support, protection from predators, and environmental factors [ 1 ]. Biomineralization in mollusks offers a wide range of microstructures and evolutionary origins [ 2 ]. Furthermore, after coral mineralization, the secretion of shells by mollusks is likely one of the most prevalent and widely occurring biomineralization processes in the metazoan realm [ 3 ]. The growth of molluscan shell crystals is predominantly thought to be initiated from solution by an extracellular organic matrix. The molluscan shell is an organo-mineral biocomposite, of which inorganic minerals (CaCO) make up 9599% while organic matter constitutes 0.15% [ 4 ]. During molluscan shell formation, the mantle tissue secretes organic matter (carbohydrates, lipids, proteins, glycoproteins, peptides, chitin, and polysaccharides), and inorganic ions are transported to the extrapallial space and deposited

**URL:** <https://www.mdpi.com/2079-7737/13/11/944>

**Title:** Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors.

**Publication Date:** 18/11/2024

**Abstract:** FOSTER CITY, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (Nasdaq TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Heather Turner, J.D., former Chief Executive Officer at Carmot Therapeutics, Inc., to the Companys Board of Directors, effective immediately. In conjunction with Ms. Turners appointment, Ann E. Taylor, M.D., is stepping down from the Board of Directors following more than three years of service. It is my pleasure to welcome Heather to the Terns Board, and I am confident she will be a valued thought partner. Heather brings relevant sector expertise in obesity and oncology and a deep understanding of the development of therapeutic products from research and development through to commercialization. We look forward to her insights and contribution to the strategic decisions that will strengthen and drive

**URL:** <https://finance.yahoo.com/news/terns-pharmaceuticals-appoints-heather-turner-210500419.html?.tsrc=rss>

**Title:** Terns Pharma Adds Ex-Carmot CEO Behind \$3.1B Roche Deal to Board.

**Publication Date:** 18/11/2024

**Abstract:** FOSTER CITY, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (Nasdaq TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Heather Turner, J.D., former Chief Executive Officer at Carmot Therapeutics, Inc., to the Companys Board of Directors, effective immediately. In conjunction with Ms. Turners appointment, Ann E. Taylor, M.D., is stepping down from the Board of Directors following more than three years of service. It is my pleasure to welcome Heather to the Terns Board, and I am confident she will be a valued thought partner. Heather brings relevant sector expertise in obesity and oncology and a deep understanding of the development of therapeutic products from research and development through to commercialization. We look forward to her insights and contribution to the strategic decisions that will strengthen and drive

**URL:** <https://www.stocktitan.net/news/TERN/terns-pharmaceuticals-appoints-heather-turner-j-d-to-board-of-5aq95t1xtck.html>

**Title:** Architect of Neural Circuits Plays Unexpected Role in Spinal Cord Development.

**Publication Date:** 18/11/2024

**Abstract:** Netrin1 is a protein that was first characterized for its axon guidance activities during embryonic development. The netrin family has been shown to play many critical roles in developmental and physiological processes beyond axon guidance. Netrin1 is involved in the progression of cancers, diabetes, and inflammatory bowel diseases. It also directs cellular differentiation across organ systems. However, no role for netrin1 directing cell fate in the developing nervous system in vivo has been described. Now, scientists at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at the University of California, Los Angeles (UCLA), have uncovered an unexpected role for netrin1 in organizing the developing spinal cord. Their

## Organization Profile

---

findings are published in Cell Reports in an article titled, Netrin1 patterns the dorsal spinal cord through modulation of Bmp signaling, and may reshape our understanding of how complex spinal circuits are established during embryonic development. This is a story

**URL:** <https://www.genengnews.com/topics/translational-medicine/architect-of-neural-circuits-plays-unexpected-role-in-spinal-cord-development/>

**Title:** Natural AI-based drug designing by modification of ascorbic acid and curcumin to combat bupropion toxicity by using molecular dynamics study - Scientific Reports.

**Publication Date:** 18/11/2024

**Abstract:** Bupropion, a widely employed insecticide in agricultural practices, has elicited significant apprehension due to its prospective deleterious effects on non-target organisms and ecological systems. Its enduring presence in terrestrial and aquatic environments presents potential hazards to human health and biodiversity, thereby necessitating the investigation of safer alternatives or strategies for mitigation. The research focuses on five principal receptors CAT (Catalase), IL-1B (Interleukin-1 Beta), IL-6 (Interleukin-6), TNF-alpha (Tumor Necrosis Factor-alpha), and SOD (Superoxide Dismutase). These receptors are integral to the processes of inflammation, oxidative stress, and immune responses, rendering them critical for comprehending the biochemical pathways affected by toxic substances and the potential for protective interventions. The investigation employed WADDAICA (Webserver-Aided Drug Design by Artificial Intelligence) to formulate AI-driven pharmaceuticals, complemented by ADME (Absorption, Distribution, Metabolism, Excretion) evaluations, Molecular Dynamics (MD) simulations, as well as MMGBSA and MMPBSA methodologies to examine the stability and interactions of the compounds with the designated

**URL:** <https://www.nature.com/articles/s41598-024-79275-5>

**Title:** Preparing safe harbor for MAGA regrets.

**Publication Date:** 18/11/2024

**Abstract:** President-elect Donald Trump and his MAGA regime have promised revenge and retribution against a range of targeted groups such as the Democrats, the deep state and the globalists, the Left, liberals, Woke, the news media, i.e. the enemy of the people, nonwhite illegal aliens, the LGBTQ community (specifically transgender people) and a range of other groups. Trump's selections for his Cabinet are distinguished both by their personal loyalty to him as well as ferocity in pursuing his personal and political enemies. Trump has repeatedly threatened to remove these enemies within from society by using the Alien Enemies Act, the Insurrection Act and other means including prison. All indications suggest that Trump's dictatorial presidency will begin by targeting those groups and individuals who are the enemy on day one. On the other hand, Trump has repeatedly promised to pardon his followers who attacked the Capitol as part of his coup attempt on

**URL:** <https://www.inkl.com/news/preparing-safe-harbor-for-maga-regrets>

## Social Links

<https://www.linkedin.com/school/ucla>

<https://www.facebook.com/UCLA>

<https://twitter.com/UCLA>

## References

N/A